DBV Technologies S.A. (EPA:DBV)
2.102
-0.032 (-1.50%)
Nov 12, 2026, 9:25 AM CET
DBV Technologies Revenue
DBV Technologies had revenue of $1.60M USD in the quarter ending September 30, 2026, a decrease of -42.86%. This brings the company's total for the last twelve months to $3.84M, down -31.63% year-over-year. In the year 2025, DBV Technologies had annual revenue of $5.64M with 35.77% growth. That makes DBV Technologies the 40,939th largest company in the world by revenue and 539th in France.
Revenue (ttm)
$3.84M
Revenue Growth
-31.63%
P/S Ratio
203.81
Revenue / Employee
$21.43K
Employees
179
Market Cap
660.46M EUR
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.64M | 1.49M | 35.77% |
| Dec 31, 2024 | 4.15M | -11.58M | -73.61% |
| Dec 31, 2023 | 15.73M | 10.88M | 224.69% |
| Dec 31, 2022 | 4.84M | -864.00K | -15.14% |
| Dec 31, 2021 | 5.71M | -5.57M | -49.38% |
| Dec 31, 2020 | 11.28M | -3.43M | -23.33% |
| Dec 31, 2019 | 14.71M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 142.94M |
| Genfit | 59.49M |
| Cellectis | 55.86M |
| MedinCell | 24.28M |
| Nanobiotix | 11.51M |
| Innate Pharma | 9.81M |
| Sensorion | 6.16M |
| Transgene | 5.62M |
DBV Technologies News
- 2 days ago - DBV Technologies Prepares Peanut Patch Launch as FDA Filing Decision Nears - MarketBeat
- 2 days ago - DBV Technologies Prepares Peanut Patch Launch as FDA Filing Decision Nears - Nasdaq
- 2 days ago - DBV Technologies Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 9 days ago - DBV Technologies to Participate in Upcoming November Investor Conferences - GlobeNewsWire
- 12 days ago - DBV Technologies price target lowered to $46 from $51 at Guggenheim - TheFly
- 13 days ago - DBV sinks after warning cash not sufficient to fund operations - TheFly
- 13 days ago - DBV Technologies price target lowered to $47 from $55 at Citizens - TheFly
- 13 days ago - DBV Technologies Report Wider Q3 Loss, Advances Peanut Allergy Patch Toward Potential Launch - Nasdaq